As many of you know, Benlysta® is the first treatment developed specifically for lupus since the disease was identified in the mid-1800's. This treatment represents a ray of hope that new safe, effective and tolerable treatments can be developed for the more than five million people around the world living with lupus.
The United Kingdom's (UK) National Institute for Health and Clinical Excellence (NICE) recently released its preliminary recommendation to NOT cover the cost of Benlysta® through the National Health Service.Their preliminary recommendation could have a devastating international impact on the survival of this important new treatment, and it may have a chilling effect on the future development of new lupus drugs thereby denying physicians and patients appropriate treatment options.
Join us in our call to action by urging NICE to recommend that the United Kingdom's National Health Service provide coverage of Benlysta® by October 20.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment